在标准或减少剂量单抗血小板治疗下使用Derivo 2Heal流转器的初始经验
Aycan Uysal1, Ferdi Cay1, Sinan Balcı1
1From the Hacettepe University Faculty of Medicine (A.U., F.C., S.B, A.A.), Ankara, Turkey.
AJNR. American journal of neuroradiology
|July 18, 2024
概括
涂有纤维素和肝素的Derivo 2Heal (D2H) 流量转移器在治疗脑动脉瘤方面显示出有前途的安全性和有效性. 这项初步研究表明可能减少并发症和有利的闭塞率,需要进一步调查.
科学领域:
- 神经内血管外科手术是一种神经内血管手术.
- 医疗器械技术 医疗器械技术
- 脑血管疾病管理
背景情况:
- 转流器的目的是减少血栓栓塞并发症和残留动脉瘤.
- 表面修饰和涂料是流转器技术的最新进展.
研究的目的:
- 评估Derivo 2Heal (D2H) 装置的临床实用性,D2H是一种新的纤维素和肝素涂层流量转移器.
主要方法:
- 用单个D2H装置治疗的患者的回顾性评估.
- 监测包括血小板功能测试和单次抗血小板治疗 (克洛皮多格雷尔或普拉苏格雷尔).
主要成果:
- 20名患有26个动脉瘤的患者接受了治疗;3名患者出现了下关节出血.
- 没有发生任何技术故障;2个轻微的不良事件是自我限制和非血栓性.
- 在早期和中期随访中观察到有利的闭塞率 (高达91.7%).
结论:
- D2H装置表明没有永久的神经缺陷和有利的闭塞率.
- 纤维素和肝素涂层可以提高流量转移的安全性和有效性.
- 需要进一步的比较研究来验证这些发现与其他设备相比.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
510
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
510
Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Formation of the Platelet Plug
5.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.7K


